Navigation Links
Haemacure Discloses Positive Results of a preclinical study of its fibrin sealant in adhesion prevention and opens a new opportunity in a market with a significant unmet medical need
Date:4/10/2008

HAE:TSX

MONTREAL, April 10 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX : HAE), a Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization, disclosed today the results of a preclinical study it recently conducted on the use of its proprietary lead product candidate, the human fibrin sealant Hemaseel(R)HMN, in preventing the formation of post-surgical adhesions.

The study was conducted on 16 rabbits that underwent open gynaecologic surgery in a uterine horn model. In preclinical testing, Hameacure's fibrin sealant was found to be significantly superior to the control group in preventing the formation of post-surgical tissue adhesion. It was also found to be superior to historical data disclosed in published literature for GYNECARE INTERCEED(TM)(TC7) Absorbable Adhesion Barrier, marketed by Ethicon, Inc.

These preclinical results are strategically significant as Haemacure's current fibrin sealant haemostasis formulation was used in this study. Initial analysis indicates that no change in the formulation or the manufacturing of Haemacure's fibrin sealant will be required to pursue an adhesion prevention indication. The safety and manufacturing information applicable to an IND to conduct adhesion prevention trials using Haemacure's fibrin sealant is identical to the information that will be included in the IND amendment to be filed later this year for the haemostasis indication. It is likely that adhesion prevention-specific preclinical data, clinical protocols and programs will also be required.

The use of Haemacure's current fibrin sealant haemostasis formulation for adhesion prevention could significantly accelerate time to market for this indication, by three to five years. This reduced timeframe accelerates Haemacure's ability to address a significant unmet medical need with an additional indication for its fibrin sealan
'/>"/>

SOURCE Haemacure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Haemacure Reports on its annual general and special meeting of shareholders
2. Media Invitation - Annual General and Special Meeting of Shareholders of Haemacure
3. Haemacure Announces Details of its Annual General and Special Meeting of Shareholders
4. Haemacure announces webcast of presentation at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conferencec
5. Haemacure Adopts Strategy for "First-Patient-In" Fibrin Sealant Pivotal Clinical Trials
6. Haemacure Reports Third Quarter 2007 Results
7. Stryker Discloses Informal Inquiry Made by United States Securities and Exchange Commission
8. Actor Joe Pantoliano Discloses Depression; Talks About His Latest Movie and His Sensitive Side
9. Increasing positive experiences decreases depression symptoms in patients with multiple sclerosis
10. Disease Management Programs that Focus on Needs of Chronically Ill Patients Can Provide Positive, Cost-Effective Results
11. Dead Skunk Tests Positive For Rabies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... October 25, 2014 TASC (Total ... and other benefits account management services, announces the ... employers save on taxes, reduce administrative workload, and ... tax savings and the efficient handling of complex, ... Suite that best meets their goals and objectives. ...
(Date:10/25/2014)... 2014 The federal judge overseeing ... ) filed against Boston Scientific Corp. in the ... Southern District of West Virginia has denied a ... in a group of cases filed on behalf ... October 21st, U.S. District Judge Joseph R. Goodwin ...
(Date:10/25/2014)... 2014 (HealthDay News) -- Not getting the right amount ... a new study suggests. Those who sleep less ... per night may be more prone to developing the ... report. The study authors concluded that duration and quality ... patients with inflammatory bowel diseases. "Both short and ...
(Date:10/25/2014)... (HealthDay News) -- October,s shorter, darker days can trigger ... according to an expert. People affected by ... tired, lack motivation and even have trouble getting out ... suicide, said Dr. Angelos Halaris, a professor in the ... Chicago Stitch School of Medicine. "Seasonal affective disorder ...
(Date:10/22/2014)... Isabel Healthcare will participate ... (ASAHP) Conference on October 22-24 in Las Vegas, NV. ... a panel discussion on Technology in Health Professions Education ... a diagnostic decision support tool and clinical education platform ... students and clinical learners. The Isabel tools help clinicians ...
Breaking Medicine News(10 mins):Health News:TASC’s New Suites Offer Tax Savings and Protection 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2
... for estrogen-sensitive tumor types, study found , , SUNDAY, April ... amounts, increases the risk of breast cancer and particularly ... shows. , The findings, expected to be presented Sunday ... Cancer Research, in San Diego, are followed by a ...
... Spectrometer is suitable for use in ... potentially explosive atmospheres, PITTSBURGH, April ... The MAX300-IGX Industrial Mass Spectrometer,is suitable for use in potentially ... obtained ATEX,approval for installations in Zone 1 areas. The MAX300-IGX ...
... the University of Pennsylvania School of Medicine and Abramson ... the American Association for Cancer Research that combining two ... lines. The team is currently designing a trial to ... is resistant to many chemotherapies and to cell-death inducing ...
... Calif., April 12 Over 300,healthcare workers at Coastal ... SEIU United Healthcare Workers - West (UHW) in a,secret-ballot ... "Uniting with thousands of other caregivers as a ... difference on the things that matter most," said,Ruth Calderon, ...
... YMCA Healthy Kids Day Saturday, April 12 ... Calif., April 11 The Mt. Diablo Region,YMCA will join ... Kids Day on Saturday, April 12 from 9 a.m. to ... Irvin Deutscher Family YMCA.,An opportunity for kids and families to ...
... researchers got paid but more upset when they owned ... volunteers in clinical studies aren,t overly concerned if researchers ... trust, suggests a U.S. study. , "Though peoples, willingness ... not suffer substantially based on the types of financial ...
Cached Medicine News:Health News:Drinking May Raise Breast Cancer Risk 2Health News:Extrel CMS Announces ATEX Approval for Process Mass Spectrometer 2Health News:Penn researchers find targeted therapy combination overcomes treatment resistance in liver cancer 2Health News:Coastal Communities Hospital Workers Join United Healthcare Workers 2Health News:The Mt. Diablo Region YMCA Invites Families to 'Put Play in Your Day' and Bring Healthy Habits Home During the Nation's Largest Health Day for Children and Families 2Health News:The Mt. Diablo Region YMCA Invites Families to 'Put Play in Your Day' and Bring Healthy Habits Home During the Nation's Largest Health Day for Children and Families 3Health News:Clinical Trial Volunteers Uneasy About Some Financial Ties 2
(Date:10/25/2014)... --  Metanome, Inc. , a Houston ... was the genomic sequencing provider for Seres Health,s ( ... of SER 109, an Ecobiotic® therapeutic for the treatment ... (CDI). Metanome has provided genomic sequencing services ... Such genomic characterization has enabled the study of the ...
(Date:10/25/2014)... 2014 Best Practices designed the Medical ... a forum for sharing insights about the key ... mechanism for creating and sharing solutions through three ... from the Medical Affairs Consortium survey. ... the first roundtable of the 2014-2015 Medical Affairs ...
(Date:10/22/2014)... 22, 2014  Rescheduling of hydrocodone combination products ... pain market, according to a new primary market ... providing market research and consultation exclusively in the ... http://photos.prnewswire.com/prnh/20141021/153440 In August, ... combination products from Schedule III to Schedule II ...
Breaking Medicine Technology:Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2Strong Participation in Best Practices' Medical Affairs Consortium Survey 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3
... COLLEGEVILLE, Pa., March 30, 2007 /PRNewswire-FirstCall/ --,Wyeth ... Inc. and Lundbeck A/S presented clinical study,results ... this,week. Safety analyses suggest bifeprunox, an investigational,treatment ... with a favorable weight and lipid profile, ...
... is STD Awareness Month: Time to Pay Attention ... 2007 /PRNewswire/ -- During,National Sexually Transmitted Disease (STD) ... awareness of, and,testing for, trichomoniasis (also known as ... States. Awareness of the condition,remains low, despite the ...
Cached Medicine Technology:Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 2Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 3Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 4Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 5Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 6Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million,Annually 2Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million,Annually 3
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products: